<div>
  <ul>
    <li>
      <p>
        GeneDx has partnered with Healthcare Tech company Komodo Health to provide access to GeneDx's rare disease dataset, which includes data from over 500,000 exomes. The dataset will be accessible through Komodo Health's MapEnhance feature of the proprietary Healthcare Map platform.
      </p>
    </li>
    <li>
      <p>
        The partnership makes use of GeneDx's in-depth rare disease data and Komodo Health's comprehensive view of patient journeys. This collaboration is aimed to enhance the development of precision medicine by providing biopharmaceutical companies with a repository of genetic data to identify new therapeutic targets and accelerate clinical trials.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Komodo Health is a biotechnology company that uses AI to gather and organize big sets of healthcare data obtained from 100+ medical sources and over 330 million individual patients. It has built a &ldquo;healthcare map,&rdquo; which collects and combines healthcare data throughout a patient&rsquo;s journey to generate insights that can be used by life sciences companies, drug developers, and insurance providers.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <b></b>
    <a href="https://www.globenewswire.com/news-release/2024/04/23/2867664/0/en/GeneDx-Announces-Partnership-with-Komodo-Health-to-Expand-Access-to-World-s-Largest-Rare-Disease-Dataset.html">
      <b>Press release</b>
    </a>
    <b></b>
  </p>
  <p>
    <b>
    </b>
  </p>
</div>


Precision Medicine

PROMINENT_CATEGORY

<div>
 <p>GeneDx has formed a strategic alliance with Komodo Health to share access to their broad dataset of rare diseases, encompassing data from over half a million exomes. The dataset will be integrated into Komodo Health's proprietary Healthcare Map platform through the MapEnhance feature.</p>
 <p>This collaborative venture leverages GeneDx's extensive rare disease data and Komodo Health's holistic interpretation of patient journeys. The main goal is to promote the advancement of precision medicine, offering biopharmaceutical entities access to a wealth of genetic data, which will help them pinpoint new therapeutic targets and hasten clinical trials. </p>
 <p>Komodo Health, a biotech entity, leverages AI to assemble and arrange large volumes of healthcare data gathered from more than a hundred medical sources and over 330 million individual patients. They have devised a “healthcare map,” which aggregates healthcare data throughout a patient’s journey, producing invaluable insights which can be utilized by life sciences companies, drug developers, and insurance providers.</p>
</div>

GeneDx partners with Komodo Health to expand access to one of the largest rare disease datasets globally

DISRUPTOR_PRESENT

INCUMBENTS_PRESENT

<div>
  <ul>
    <li>
      <p>The New York Center for Rare Diseases has partnered with genetic testing and bioinformatics company GeneDx, biotechnology company Pacific Biosciences (PacBio), and Google Health on genetic diagnoses for families in the Bronx living with rare diseases.</p>
    </li>
    <li>
      <p>A pilot project will perform genomic testing on 50 patient-parent trios to see if PacBio's long-read sequencing can identify genetic alterations. Further, in order to analyze these genomes with PacBio's HiFi DNA and RNA sequencing, GeneDx expects to perform short-read whole-genome sequencing. The genomic data would be returned to Albert Einstein College of Medicine for analysis.</p>
    </li>
  </ul>
</div>

The New York Center for Rare Diseases (NYCRD) partners with Google Health and multiple genetic testing companies for genetic testing pilot

GeneDx reports Q2 2023 results; misses analysts’ estimates but revenue increases

GeneDx, PacBio, and the University of Washington are collaborating to explore the potential of long-read whole-genome sequencing (WGS) in diagnosing genetic conditions in pediatric patients. GeneDx will conduct WGS sequencing and analysis on samples from 350 individuals, aiming to uncover genetic variants that traditional short-read sequencing methods may miss. The PacBio Revio sequencing system will be used for the long-read WGS, with Google providing funding and support to improve healthcare outcomes through AI-driven solutions and accurate sequencing. The study's results will contribute to the CoLoRS database.

All Updates

GeneDx partners with Komodo Health to expand access to one of the largest rare disease datasets globally

The New York Center for Rare Diseases (NYCRD) partners with Google Health and multiple genetic testing companies for genetic testing pilot

GeneDx reports Q2 2023 results; misses analysts’ estimates but revenue increases

PacBio and GeneDx collaborate to enhance pediatric genetic diagnosis

GeneDx reports Q1 2023 results; misses analysts’ estimates

GeneDx plans USD 150 million in public offering

Precision medicine startups announce preliminary earnings for 2022

Sema4 continues restructuring Q3 2022; revenue doubles YoY

Sema4 partners with the GUARDIAN for genomic newborn screening study

Sema4 continues restructuring Q2 2022; revenue slips 23% YoY